URO

LEADING WOMEN'S WELLNESS BRAND O POSITIV ANNOUNCES THE LAUNCH OF WILLO HAIR GROWTH SUPPORT CAPSULES

Retrieved on: 
Thursday, November 9, 2023
Trial of the century, Education, Health, PMS, Menopause, Clinical professor, Vitamin, Hair, FLO, Amazon, DHT, Selenium, Pregnancy, Antioxidant, Mineral, Poverty, Oxidative stress, LOS, Arginine, Zinc, Scalp, Woman, URO, Nutrient, Biotin, Hearing, Mayo Clinic, Silicon, Iron, Cosmetics, Birth control, Dietary supplement, Capsule

LOS ANGELES, Nov. 9, 2023 /PRNewswire/ -- O Positiv, the supplement brand breaking taboos in women's health, introduces their newest product WILLO Hair Growth Support Capsules.

Key Points: 
  • Supplements Support Healthy Hair Growth and Thicker, Fuller Hair
    LOS ANGELES, Nov. 9, 2023 /PRNewswire/ -- O Positiv , the supplement brand breaking taboos in women's health, introduces their newest product WILLO Hair Growth Support Capsules .
  • WILLO Hair Growth Support Capsules represent O Positiv's dedication to addressing another common yet often unspoken issue for women– thinning hair.
  • Each WILLO Hair Growth Support Capsules not only contain Lustriva® but also a variety of other vital ingredients.
  • WILLO Hair Growth Support Capsules retail for $69.99 one time, $59.99 for a subscription at opositiv.com and amazon.com .

LEADING WOMEN'S WELLNESS BRAND O POSITIV ANNOUNCES THE LAUNCH OF URO BLADDER CONTROL

Retrieved on: 
Wednesday, October 4, 2023
Mayo Clinic, Zinc, Education, Urine, Sleep, Woman, Capsule, Dicarboxylic acid, Trial of the century, PMS, Iron, Frequency, Prevalence, LOS, URO, Health, FLO, Dietary supplement

LOS ANGELES, Calif., Oct. 4, 2023 /PRNewswire/ -- O Positiv, the supplement brand breaking taboos in women's health, introduces their newest product URO Bladder Control Capsules.

Key Points: 
  • Scientifically Formulated with Ingredients for Urinary Urgency, Frequency and Leakage
    LOS ANGELES, Calif., Oct. 4, 2023 /PRNewswire/ -- O Positiv , the supplement brand breaking taboos in women's health, introduces their newest product URO Bladder Control Capsules.
  • URO Bladder Control, once again, tackles an issue that many women suffer from in silence.
  • Its scientifically formulated ingredients support healthy bladder control and normal bladder function.
  • In a clinical study using the ingredients in URO Bladder Support, 90% of participants reported that daily supplementation was helpful at addressing their urinary bladder issues.

LEADING WOMEN'S WELLNESS BRAND O POSITIV ANNOUNCES THE LAUNCH OF FLO PMS COMPLETE

Retrieved on: 
Thursday, June 15, 2023
Poverty, Luteal phase, Education, Caffeine, Ovulation, Dysmenorrhea, Follicular phase, Woman, Cramp, Positiv, Political positivism, Gamer, Tablet, Mepyramine, Sibling, PMS, Menstruation, Patient, Bloating, Health, URO, Amazon, Skin, FLO, Fatigue, Maintenance (technical), Birth control, Pharmaceutical industry, Paracetamol, Capsule, MD

LOS ANGELES, June 15, 2023 /PRNewswire/ -- Today, O Positiv, the women's health brand behind FLO, the first-ever PMS support supplement on the market, introduces their newest product FLO PMS Complete. 

Key Points: 
  • LOS ANGELES, June 15, 2023 /PRNewswire/ -- Today, O Positiv , the women's health brand behind FLO , the first-ever PMS support supplement on the market, introduces their newest product FLO PMS Complete .
  • Since launching the FLO PMS Gummy in December 2018, O Positiv has positioned themselves as a premiere wellness brand with a range of products to address vaginal, digestive, skin, menstrual and menopausal health.
  • Each FLO PMS Complete tablet contains Acetaminophen, Caffeine and Pyrilamine Maleate to help alleviate menstrual and PMS related discomfort, such as cramps, aches, bloating, fatigue and water-related weight gain.
  • Now, with FLO Complete available, they can continue to use the trusted products of O Positiv for quick relief."

Women's Health Brand O Positiv Expands Into The Menopause Category With The First-Ever Menopause Gummy Vitamin

Retrieved on: 
Wednesday, January 18, 2023
Flash, URO, Immunity, OBGYN, Gummy candy, Menopause, Capsule, PMS, LOS, Mood Swings, Product innovation, Vitex agnus-castus, Woman, FLO, Taboo, Patient, Academic Model Providing Access to Healthcare (AMPATH), Vitamin B6, Actaea racemosa, Vitamin, Progesterone, Personal lubricant, UTI, Birth control, Dietary supplement, Withania somnifera

LOS ANGELES, Jan. 18, 2023 /PRNewswire/ -- Following the creation of their hero product, FLO Vitamins, and the recent success of their MENO Capsule launch, O Positiv is continuing to target menopause-aged women head on with its latest product launch today, MENO Gummies. The all-natural, hormone-free gummies are formulated with the same research-backed ingredients as the brand's MENO capsules, all of which have been shown to help alleviate common menopause-related symptoms.

Key Points: 
  • Since the launch of their MENO Capsules back in May, the demand for more menopause support has grown significantly, incentivizing the brand to create the formula in gummy format.
  • Watching the Bitton sibling's mother, Mary Kay Bitton, suffer from a debilitating menopause experience further pushed them to expedite the process of creating this much-needed product.
  • For my patients that are seeking natural solutions to symptoms like hot flashes and night sweats, I recommend taking MENO."
  • O Positiv was the first brand to take on PMS with its flavorful, science-backed gummy supplement FLO , which allowed the company to expand its horizon to address equally common women's health issues.

Medtronic announces first patient enrolled in U.S. clinical trial for Hugo™ robotic-assisted surgery system

Retrieved on: 
Thursday, December 15, 2022
Security (finance), Urology, Investigational device exemption, Nephrectomy, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Duke University Hospital, Diagnosis, Adoption of electronic medical records in U.S. hospitals, Partnership, Hugo, Patient, Sale, Hospital, Swedish Health Services, NYSE, Disease, RAS, FDA, Pain, Sofie (surgical robot), Clinical trial, URO, Goldfarb, Safety, Gynaecology, Health, General surgery, Dentistry, Medical device, Medtronic, Expansion

DUBLIN, Dec. 15, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global healthcare technology leader, today announced the first patient enrolled in the Expand URO U.S. clinical trial for the Hugo™ robotic-assisted surgery (RAS) system. The robotic-assisted prostatectomy procedure was performed by Dr. Michael R. Abern at Duke University Hospital in Durham, N.C.

Key Points: 
  • "Robotic-assisted surgery provides many benefits within my specialty of urology, and I'm proud to have performed the first U.S. clinical trial case with the Medtronic Hugo RAS system."
  • The Expand URO clinical trial is being conducted pursuant to an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA).
  • "4
    The Hugo RAS system, combined with Touch Surgery Enterprise, offers a smart, digitally enabled surgical experience.
  • Regulatory requirements and status in individual countries and regions will determine market availability of the Hugo RAS system and approved indications.

The Company Behind "FLO Vitamins" Enters Vaginal Health Space With New Science-Backed Collection Of Vaginal Probiotic And Urinary Tract Supplements

Retrieved on: 
Tuesday, September 13, 2022
Probiotic, VP, Time-invariant system, Health, FLO, Gaps, Mannose, Woman, Risk, FDA, Food, Urinary tract infection, Vagina, UTI, Digestion, MOTO, Metabolism, Maintenance, PMS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Menopause, Instagram, Self-care, Solution, Bacteria, Collection, URO, Water, Birth control, Dietary supplement, Capsule

LOS ANGELES, Sept. 13, 2022 /PRNewswire/ -- Women's health brand O Positiv is entering the vaginal health space with its latest supplement collection URO, which launches today. The non-GMO, vegan and major-allergen free Vaginal Probiotic (URO VP) and Urinary Tract (URO UT) Capsules are intended to support overall vaginal balance, ultimately helping with vaginal and urinary tract health.

Key Points: 
  • LOS ANGELES, Sept. 13, 2022 /PRNewswire/ -- Women's health brand O Positiv is entering the vaginal health space with its latest supplement collection URO, which launches today.
  • The non-GMO, vegan and major-allergen free Vaginal Probiotic (URO VP) and Urinary Tract (URO UT) Capsules are intended to support overall vaginal balance, ultimately helping with vaginal and urinary tract health.
  • Urinary Tract Capsules (URO UT): An antibiotic-free solution that leverages clinically-studied Pacran Cranberry Extract, D-Mannose and Vitamin C to promote optimal urinary tract health.
  • URO UT's best-in-class ingredients work to help maintain healthy levels of bacteria in the urinary tract and promote urinary frequency.

Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021

Retrieved on: 
Monday, November 1, 2021
Linda, EMANATE, Gene, Health informatics, Microdeletion syndrome, Marshfield Clinic, Government budget balance, Pediatrics, SH2B1, Lists of diseases, BBS, Sigma-1 receptor, GLOBE, NIHR, Research, Body mass index, Anti-obesity medication, University College London, SIM1, Publication, Clinical research center, Pediatric endocrinology, Polyphagia, Department, Medical Affairs Bureau, UCL Great Ormond Street Institute of Child Health, Faculty, University of Cambridge, SRC1, MC4R, BMI, Nasdaq, All, Interdisciplinary Association for Population Health Science, University, SCM, Endocrine Society, Impact, ESPE, Associate Director of National Intelligence and Chief Information Officer, Weight loss, Doctor of Science, Review, URO, Adult, European Society for Medical Oncology, MMSc, Pharmaceutical industry, Medicine, Medical imaging, Life insurance, Medical device

BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, this week presented the first-ever data on the health-related quality of life (HRQOL) and experience of patients with Bardet-Biedl syndrome (BBS) who were treated in its Phase 3 trial of setmelanotide at The Obesity Society’s ObesityWeek®, a virtual conference that runs from Nov. 1 to 5.   

Key Points: 
  • Elizabeth Forsythe, Ph.D., Great Ormond Street Institute of Child Health, Faculty of Population Health Sciences, University College London, presented a poster entitled, Quality of Life in Patients with Bardet-Biedl Syndrome in a Setmelanotide Phase 3 Trial.
  • Rhythm also presented new hunger reduction data from its exploratory Phase 2 Basket Trial evaluating setmelanotide in patients with obesity due to variants of the SRC1 gene or the SH2B1 gene.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity.
  • IMCIVREE is the first-ever FDA-approved and EC- and MHRA-authorized therapy for patients with these rare genetic diseases of obesity.